CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for China Resrcs Boya Bio phrmctcl Grp CoLtd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

China Resrcs Boya Bio phrmctcl Grp CoLtd
No. 333
Huiquan Road, High-tech Industrial Park
Phone: +86 7948264398p:+86 7948264398 FUZHOU, JGX  344000  China Ticker: 300294300294
Business Summary
China Resources Boya Bio-pharmaceutical Group Co Ltd, formerly Boya Bio-pharmaceutical Group Co Ltd, is a China-based company principally engaged in the research, development, production and distribution of blood products. The Company's main products include human albumin, freeze-drying intravenous injection human immune globulin, human immune globulin, hepatitis B human immune globulin, hydrophobia human immune globulin, human fibrinogen, metformin hydrochloride, calcium dobesilate capsules, glimepiride and pioglitazone hydrochloride dispersible tablets, among others. The Company's blood products are mainly used in the treatment of tumor, liver diseases and diabetes, among others. The Company also provides diabetic pharmaceuticals and biochemical pharmaceuticals. The Company distributes its products mainly in domestic market.
(Source: F-4)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023Yes----

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
2834 Pharmaceutical preparations
5122 Drugs, drug proprietaries, and druggists' sundries

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board KaiQiu 55 10/25/2023 10/25/2023
President, Director XiaomingLiang 57 2/3/2021 2/3/2021
Chief Financial Officer, Vice President, Secretary of the Board, Director HuachengLiang 42 3/21/2024 12/10/2021
8 additional Officers and Directors records available in full report.

General Information
Number of Employees: 1,444 (As of 12/31/2023)
Outstanding Shares: 504,248,738 (As of 12/31/2023)
Shareholders: 20,580
Stock Exchange: SHE
Fax Number: +86 7948237323


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 18, 2024